Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $9.88, but opened at $10.38. Pharming Group shares last traded at $10.50, with a volume of 479 shares.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on PHAR shares. HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer raised their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Get Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
The stock has a market capitalization of $691.25 million, a price-to-earnings ratio of -50.80 and a beta of 0.02. The business's fifty day moving average price is $10.46 and its 200-day moving average price is $9.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The business had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. On average, research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
